Cambridge Consultants

Cambridge Consultants has developed EnfuseNet, a breakthrough Artificial Intelligence (AI) system for autonomous vehicles - a low-cost system that generates high-resolution depth data for vehicle perception technology. 

Leading medical device development companies have been asked by the UK Government to develop and manufacture ventilators at massive speed.

Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the successful close of its Series B funding. 

MIT spin-out company Kytopen has engaged Cambridge Consultants to co-develop the first Flowfect™ system.

Breakthrough innovation specialist Cambridge Consultants has partnered with Redbarn Group to develop VeriTherm, a fast and simple tool to verify the thermal performance of new buildings. It points to a future where every new home meets thermal specifications.

BacillAi is a concept system using AI and low-cost hardware to improve treatment monitoring of TB in resource-limited countries, part of our mission to move AI beyond the hype, addressing practical, global challenges.

Cambridge Consultants joins a global network of design service companies that have been selected and endorsed by Arm, uniting two leaders of the Cambridge technology cluster.

Cambridge Consultants introduces Fafaza - a practical example of ‘AI at the edge’: a self-contained agricultural precision spraying system that uses low-cost processors that can identify, classify and apply treatment in real time.

Cambridge Consultants partners with Collusion 2019, a public art exhibition which opens tomorrow (Friday April 12th 2019). The exhibition invites visitors to explore society’s relationship with emerging technologies, including artificial intelligence (AI), data culture, and augmented reality, in a series of six interactive artworks.